• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ADC Therapeutics SA (Amendment)

    2/14/24 4:26:23 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADCT alert in real time by email
    SC 13G/A 1 tm245846d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)

     

    ADC Therapeutics SA

    (Name of Issuer)

     

    Common Shares

    (Title of Class of Securities)

     

    H0036K147

     

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. H0036K147

    1

    Name of Reporting Person

     

    Redmile Group, LLC

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

     

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

     

     

     

     

    number of
    shares beneficially
    owned by
    each
    reporting
    person with

     

     

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    15,328,317 (1)

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    15,328,317 (1)

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    15,328,317 (1)

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    18.8%(2)

     

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

     

     

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s common shares (“Common Stock”) is comprised of 15,328,317 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, including RedCo II Master Fund, L.P., which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (2) Percentage based on 81,516,563 shares of Common Stock, which is the weighted average number of shares outstanding for the nine months ended September 30, 2023, as reported by the Issuers in its unaudited IFRS Condensed Consolidated Interim Financial Statements (the “Interim Financial Statements”) on Form 6-K filed with the SEC on November 7, 2023 (“Form 6-K”).

     

     

     

     

    CUSIP No. H0036K147

    1

    Name of Reporting Person

     

    Jeremy C. Green

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

     

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United Kingdom

     

     

     

     

     

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

     

     

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    15,328,317 (3)

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    15,328,317 (3)

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    15,328,317 (3)

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    18.8%(4)

     

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

     

     

     

    (3) Jeremy C. Green’s beneficial ownership of the Common Stock is comprised of 15,328,317 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, including RedCo II Master Fund, L.P., which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (4) Percentage based on 81,516,563 shares of Common Stock, which is the weighted average number of shares outstanding for the nine months ended September 30, 2023, as reported in the Interim Financial Statements on Form 6-K.

     

     

     

     

    CUSIP No. H0036K147

    1

    Name of Reporting Person

     

    RedCo II Master Fund, L.P.

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

     

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Cayman Islands

     

     

     

     

     

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

     

     

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    12,595,040 (5)

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    12,595,040 (5)

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    12,595,040 (5)

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    15.5%(6)

     

    12

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

     

    (5) The shares of Common Stock reported as beneficially owned by RedCo II in this Schedule 13G represent the shares of Common Stock held directly by RedCo II.

    (6) Percentage based on 81,516,563 shares of Common Stock, which is the weighted average number of shares outstanding for the nine months ended September 30, 2023, as reported in the Interim Financial Statements on Form 6-K.

     

     

     

     

    Item 1.

     

    (a)Name of Issuer

     

    ADC Therapeutics SA

     

    (b)Address of Issuer’s Principal Executive Offices

     

    Biopôle

    Route de la Corniche 3B

    1066 Epalinges

    Switzerland

     

    Item 2.

     

    (a)Names of Persons Filing

     

    Redmile Group, LLC

    Jeremy C. Green

    RedCo II Master Fund, L.P.

     

    (b)Address of Principal Business office or, if None, Residence

     

    Redmile Group, LLC

    One Letterman Drive

    Building D, Suite D3-300

    The Presidio of San Francisco

    San Francisco, California 94129

     

    Jeremy C. Green

    c/o Redmile Group, LLC (NY Office)

    45 W. 27th Street, Floor 11

    New York, NY 10001

     

    RedCo II Master Fund, L.P.

    c/o Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    (c)Citizenship

     

    Redmile Group, LLC: Delaware

    Jeremy C. Green: United Kingdom

    RedCo II Master Fund, L.P.: Cayman Islands

     

    (d)Title of Class of Securities

     

    Common Shares

     

    (e)CUSIP Number

     

    H0036K147

     

     

     

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         
    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
         
    (e)¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
         
    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
         
    (g)¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j)¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
         
    (k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
        __________

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Redmile Group, LLC – 15,328,317 (1)

    Jeremy C. Green – 15,328,317 (1)

    RedCo II Master Fund, L.P. – 12,595,040 (3)

     

    (b)Percent of class:

     

    Redmile Group, LLC – 18.8% (2)

    Jeremy C. Green – 18.8% (2)

    RedCo II Master Fund, L.P. – 15.5% (2)

     

    (c)Number of shares as to which Redmile Group, LLC has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    15,328,317 (1)

     

     

     

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    15,328,317 (1)

     

    Number of shares as to which Jeremy C. Green has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    15,328,317 (1)

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    15,328,317 (1)

     

    Number of shares as to which RedCo II Master Fund, L.P. has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    12,595,040 (3)

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    12,595,040 (3)

     

    (1) The Issuer’s common shares reported herein are held by certain private investment vehicles and/or sub-advised accounts, including RedCo II Master Fund, L.P., (collectively, the “Redmile Clients”) for which Redmile Group, LLC is the investment manager/adviser and, in such capacity, exercises voting and investment power over all of the common shares held by the Redmile Clients and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the principal of Redmile Group, LLC and also may be deemed to be the beneficial owner of these shares. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Pursuant to the Issuer’s articles of incorporation, no shareholders of the Issuer, including the Redmile Clients, may own or otherwise control voting rights with respect to more than 15% of the share capital, which would limit the Redmile Clients to voting 12,227,484 shares of its Common Stock (calculated in accordance with footnote (2) below).

     

    (2) Percentage based on 81,516,563 shares of Common Stock, which is the weighted average number of shares outstanding for the nine months ended September 30, 2023, as reported in the Interim Financial Statements on Form 6-K.

     

    (3) The shares of Common Stock reported as beneficially owned by RedCo II Master Fund, L.P. in this Schedule 13G represent the shares of Common Stock held directly by RedCo II Master Fund, L.P.

     

     

     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See the response to Item 4.

     

    Item 8.Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9.Notice of Dissolution of Group.

     

    N/A

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

      Redmile Group, LLC
         
         
      By: /s/ Jeremy C. Green
        Name: Jeremy C. Green
        Title: Managing Member

     

      /s/ Jeremy C. Green
      Jeremy C. Green

     

      RedCo II Master Fund, L.P. 
       
      By: RedCo II (GP), LLC, its general partner
         
         
      By: /s/ Jeremy C. Green
        Name: Jeremy C. Green
        Title: Managing Member

     

     

     

    Get the next $ADCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADCT

    DatePrice TargetRatingAnalyst
    11/8/2024$6.00Overweight
    Stephens
    5/30/2024Overweight
    Cantor Fitzgerald
    3/28/2024$11.00Buy
    Guggenheim
    8/10/2023Underweight → Neutral
    JP Morgan
    4/24/2023$7.00 → $2.00Neutral → Underperform
    BofA Securities
    12/6/2022$12.00Overweight
    CapitalOne
    11/9/2022$14.00 → $7.00Buy → Neutral
    BofA Securities
    9/21/2022$5.00Overweight
    JP Morgan
    More analyst ratings

    $ADCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ADC Therapeutics to Present at Upcoming Investor Conferences

      LAUSANNE, Switzerland, May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences: RBC Capital Markets Global Healthcare ConferenceDate: May 21, 2025Presentation Time: 10:30-10:55 a.m. ETFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive OfficerTo register for the webcast, click here. Jefferies Global Healthcare ConferenceDate: June 5, 2025Presentation Time: 9:55-10:25 a.m. ETFormat: Fireside ChatSpeaker: A

      5/15/25 7:15:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

      LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability Forty patient enrollment reached in LOTIS-7 trial dose expansion arm in patients with relapsed/refractory DLBCL Cash runway expected to fund multiple catalysts into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (

      5/14/25 8:00:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

      ZYNLONTA® plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL Safety and tolerability data were consistent with the known profiles of each agent Updated data to be shared during poster presentation at EHA2025 on Saturday, June 14 at 12:30 p.m. ET and oral presentation at ICML on Friday, June 20 at 9:00 a.m. ET LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data presentations from the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in com

      5/14/25 7:45:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

      Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

      10/13/22 1:04:01 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

      Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

      10/13/22 1:03:14 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

      Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:

      4/23/21 1:46:03 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

      SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

      11/14/24 9:00:57 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

      SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

      11/13/24 8:58:56 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

      SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

      11/13/24 8:30:55 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Wild Hans Peter acquired 9,788,944 shares (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      5/19/25 3:52:01 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • See Explanations Pfisterer Thomas disposed of 451,856 shares, decreasing direct ownership by 72% to 173,899 units (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      5/19/25 3:35:33 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Mallik Ameet covered exercise/tax liability with 26,758 shares, decreasing direct ownership by 2% to 1,552,247 units (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      5/8/25 9:14:46 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Redmile Group, Llc bought $609,000 worth of shares (200,000 units at $3.04) (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      12/13/24 9:00:14 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      7/3/24 8:00:13 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    SEC Filings

    See more
    • SEC Form 10-Q filed by ADC Therapeutics SA

      10-Q - ADC Therapeutics SA (0001771910) (Filer)

      5/14/25 4:07:39 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics SA filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ADC Therapeutics SA (0001771910) (Filer)

      5/14/25 8:14:42 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by ADC Therapeutics SA

      DEF 14A - ADC Therapeutics SA (0001771910) (Filer)

      4/21/25 9:20:30 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Leadership Updates

    Live Leadership Updates

    See more
    • Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

      £90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi

      7/8/24 2:00:00 AM ET
      $ADCT
      $CG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance
    • ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

      LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios." Th

      6/27/24 7:15:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

      LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space. Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE:ADCT) in Jan 2012 and served as its CEO since inception until May 2022. Under his leadership, ADC Therapeutics grew from a private biotech start-up to a New York

      11/15/23 3:00:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on ADC Therapeutics with a new price target

      Stephens initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $6.00

      11/8/24 7:32:36 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on ADC Therapeutics

      Cantor Fitzgerald initiated coverage of ADC Therapeutics with a rating of Overweight

      5/30/24 7:26:04 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on ADC Therapeutics with a new price target

      Guggenheim initiated coverage of ADC Therapeutics with a rating of Buy and set a new price target of $11.00

      3/28/24 7:31:32 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Financials

    Live finance-specific insights

    See more
    • ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

      LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability Forty patient enrollment reached in LOTIS-7 trial dose expansion arm in patients with relapsed/refractory DLBCL Cash runway expected to fund multiple catalysts into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (

      5/14/25 8:00:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

      LAUSANNE, Switzerland, May 8, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 8:30 a.m. EDT to report financial results for the first quarter 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event,

      5/8/25 7:15:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

      Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025 Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL; data update anticipated in late 2025 once PFS events reached $250.9M in cash as of December 31, 2024, provides runway expected to fund operations into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug c

      3/27/25 7:30:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care